$IRMD

Susi Roger E. sold $85K of IRMD (indirect holdings)

Susi Roger E. (CEO, President, Chairman) sold 924 indirectly-held shares of IRADIMED CORP (IRMD) at $91.91 on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Susi Roger E.
Published Jun 2, 2026, 6:26 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 6:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IRMD
Neutral
medium confidence
Mentioned
$IRMD
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRMDNeutralLow
01

Why it matters

Traders may briefly reassess sentiment/positioning, but the 10b5-1 designation generally lowers the probability of a new negative fundamental catalyst.

02

Market read

A disclosed insider sale can move microstructure/attention, but the pre-arranged nature makes it more of a sentiment datapoint than a catalyst.

03

What to watch

Magnitude is modest relative to typical insider holdings; without follow-on buys/sells or changes in plan parameters, signal quality is limited.

Relevance 6/10Novelty 6/10Timing: Filed today; transaction dated 2026-06-01

Background

SEC Form 4 reports an officer/director/10% owner transaction for IRMD; the sale is marked as open-market and pre-arranged under Rule 10b5-1.

Company-level read

Ticker impact

$IRMDNeutralMedium confidence
Context

IRMD CEO/President/Chairman Susi Roger sold $84,924 of IRMD shares via an open-market transaction under a 10b5-1 plan.

Expected impact

Limited, mostly sentiment/technical impact; any move likely fades unless accompanied by other catalysts.

Evidence & confidence

The filing is a routine insider transaction with a pre-arranged 10b5-1 plan, reducing interpretive weight versus discretionary selling.

Market effects

No direct sector read-through; this is company-specific insider disclosure.

None indicated.

None indicated.

Counterpoint

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.

Key entities

  • IRADIMED CORP

    Company whose shares were sold by an insider (CEO/President/Chairman) under a 10b5-1 plan.

  • Susi Roger E.

    CEO/President/Chairman and 10% owner who sold 924 shares at $91.91 on 2026-06-01.

Related articles

$IRMDMedAI 9/10

IRadimed (IRMD) Q2 2026 Earnings Call Transcript

IRadimed (IRMD) reported Q2 2026 revenue of $20.5 million, up 0.5% from $20.4 million a year earlier. GAAP diluted EPS was $0.41 versus $0.45, and non-GAAP EPS was $0.46. Gross margin fell to 74% from 78% due to higher manufacturing costs during the 3870 pump ramp. Q3 revenue guidance is $23.0 to $24.5 million; full-year 2026 revenue guidance is $91 to $96 million.

$IRMDMedAI 9/10

Iradimed Corp (IRMD): 3 Things That Stood Out From Q1 Report

Iradimed Corp (IRMD) reported Q1 2026 results on May 1. The company said revenue rose 13% year over year to $22 million and net income increased 24% to $5.8 million, or $0.45 per share. Iradimed also launched its next-generation 3870 MRI-compatible IV infusion pump in Q1, with shipments expected to begin in Q2. For Q2, it forecast revenue of $20–$21 million and GAAP EPS of $0.40–$0.44; full-year 2026 revenue of $91–$96 million and GAAP EPS of $1.90–$2.05.